PDL BioPharma Subsidiary to Acquire Hypertension Drugs from Novartis
PDL BioPharma has acquired exclusive worldwide rights to two antihypertension drugs from Novartis through an investment in a new majority-owned subsidiary. PDL said yesterday it will invest up to $294 million …
Read guide →